UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 8-K/A

(Amendment No. 1)

CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE **SECURITIES EXCHANGE ACT OF 1934**

Date of report (Date of earliest event reported): November 1, 2022 (October 31, 2022)

Acadia Healthcare Company, Inc. (Exact Name of Registrant as Specified in Its Charter)

Delaware (State or Other Jurisdiction of Incorporation)	001-35331 (Commission File Number)	45-2492228 (IRS Employer Identification No.)
6100 Tower Circle, Suite 1000 Franklin, Tennessee (Address of Principal Executive Off		37067 (Zip Code)
(Reg	(615) 861-6000 gistrant's Telephone Number, including Area	Code)
(Former 1	Not Applicable Name or Former Address, if Changed Since I	ast Report)
Check the appropriate box below if the Form 8-K filin following provisions (See General Instruction A.2. bel		ing obligation of the registrant under any of the
☐ Written communications pursuant to Rule 425 under	er the Securities Act (17 CFR 230.425)	
☐ Soliciting material pursuant to Rule 14a-12 under t	he Exchange Act (17 CFR 240.14a-12)	
☐ Pre-commencement communications pursuant to R	ule 14d-2(b) under the Exchange Act (17 CF	R 240.14d-2(b))
☐ Pre-commencement communications pursuant to R	ule 13e-4(c) under the Exchange Act (17 CF	R 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the A	act:	
Title of each class	Trading Symbol N	ame of each exchange on which registered
Common Stock, \$0.01 par value	ACHC	NASDAQ Global Select Market
Indicate by check mark whether the registrant is an em chapter) or Rule 12b-2 of the Securities Exchange Act		05 of the Securities Act of 1933 (§230.405 of this
		Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new

or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

EXPLANATORY NOTE

This Amendment No. 1 on Form 8-K/A (this "Amendment") is being filed by Acadia Healthcare Company, Inc. (the "Company") to amend the Company's Current Report on Form 8-K, filed with the U.S. Securities and Exchange Commission on October 31, 2022 (the "Original Filing"), solely to correct information reported on page 11 of the press release furnished as Exhibit 99.1 to the Original Filing (the "Earnings Release"). Within page 11 of the Earnings Release, a correction was made to the supplementary table titled "Reconciliation of Net Income Attributable to Acadia Healthcare Company, Inc. to Adjusted Income Attributable to Acadia Healthcare Company, Inc." to the line item titled "Income tax effect of adjustments to income" and the resulting calculations of Adjusted income and Adjusted income per diluted share. A corrected version of the Earnings Release is included herewith as Exhibit 99.1 and is being posted on the Company's website. This Amendment does not otherwise amend, update, or change any disclosure contained in the Original Filing other than the table on page 11 of the Earnings Release.

Item 2.02 Results of Operations and Financial Condition

Information in Item 7.01 is incorporated by reference herein to the extent applicable.

Item 7.01 Regulation FD Disclosure

On October 31, 2022, the Company issued the Earnings Release announcing, among other things, the Company's operating and financial results for the third quarter ended September 30, 3022. The corrected version of the Earnings Release is attached as Exhibit 99.1 to this Amendment and is incorporated herein by reference.

The information contained in this Current Report on Form 8-K (including the explanatory note and exhibits hereto) shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or shall they be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

Exhibit Number Description of Exhibit

99.1 Corrected Press Release dated October 31, 2022

104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURE

Date: October 31, 2022

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ACADIA HEALTHCARE COMPANY, INC.

By:/s/ Christopher L. Howard

Christopher L. Howard

Executive Vice President and General Counsel

CORRECTING and REPLACING Acadia Healthcare Reports Third Quarter 2022 Results

Same Facility Revenue Increases 10.2%

CORRECTION...by Acadia Healthcare Company, Inc.

FRANKLIN, Tenn.--(BUSINESS WIRE)--October 31, 2022--There was an inadvertent error on the supplementary table titled "Reconciliation of Net Income Attributable to Acadia Healthcare Company, Inc. to Adjusted Income Attributable to Acadia Healthcare Company, Inc." on page 11 of the previous release, within the line item titled "Income tax effect of adjustments to income" and the resulting calculations of Adjusted income and Adjusted income per diluted share in the table. The table has been corrected and there were no other changes to the release.

The updated release reads:

ACADIA HEALTHCARE REPORTS THIRD QUARTER 2022 RESULTS

Same Facility Revenue Increases 10.2%

Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced financial results for the third quarter ended September 30, 2022.

Third Quarter Highlights

- Revenue totaled \$666.7 million, an increase of 13.5% over the third quarter of 2021
- Same facility revenue increased 10.2% compared to the third quarter of 2021, including an increase in revenue per patient day of 6.9% and an increase in patient days of 3.1%
- Net income attributable to Acadia totaled \$71.1 million, or \$0.78 per diluted share, and adjusted income from continuing operations attributable to Acadia stockholders totaled \$73.3 million, or \$0.86 per diluted share, which included \$0.06 of income from the Provider Relief Fund ("PRF") established under the Coronavirus Aid, Relief, and Economic Security ("CARES") Act
- Adjusted EBITDA totaled \$162.8 million, which included \$7.7 million of income from the PRF established under the CARES Act
- Opened a de novo children's hospital in Chicago, a joint venture facility in Knoxville, and two new Comprehensive Treatment Centers ("CTCs")

Third Quarter Results

The Company reported revenue of \$666.7 million for the third quarter of 2022, compared with \$587.6 million for the third quarter of 2021. Adjusted EBITDA was \$162.8 million for the third quarter of 2022, compared with \$141.9 million for the same period last year. Excluding income from the PRF, Adjusted EBITDA was \$155.1 million for the third quarter of 2022.

The Company recorded income from the PRF of \$7.7 million in the third quarter of 2022. The Company will continue to review the remaining \$14.2 million of American Rescue Plan ("ARP") Rural Payments held on its balance sheet as of September 30, 2022, for the potential recognition of additional income. Financial guidance for 2022 does not include the recognition of additional income in the fourth quarter of 2022 beyond the \$16.2 million recorded in the nine months ended September 30, 2022.

Net income attributable to Acadia stockholders for the third quarter of 2022 was \$71.1 million, or \$0.78 per diluted share. Adjusted income from continuing operations attributable to Acadia stockholders was \$0.86 per diluted share for the third quarter of 2022. Excluding income from the PRF, adjusted income from continuing operations was \$0.80 per diluted share for the third quarter of 2022. Adjustments to income include transaction-related expenses and the income tax effect of adjustments to income. A reconciliation of all non-GAAP financial results in this press release begins on page 10.

For the third quarter of 2022, Acadia's same facility revenue increased 10.2% compared with the third quarter of 2021, including an increase in revenue per patient day of 6.9% and an increase in patient days of 3.1%.

Chris Hunter, Chief Executive Officer of Acadia Healthcare Company, remarked, "We continued to see robust demand for our behavioral healthcare services during the third quarter. We executed our strategy with favorable results across our key performance metrics including continued navigation through a tight labor market. We are fortunate to have an experienced and dedicated team of employees and clinicians across our operations who have worked tirelessly to meet the needs of those seeking treatment for mental health and substance use issues.

Strategic Investments for Long-Term Growth

"We have progressed on our key growth initiatives across all our service lines this year. We continue to make critical investments in our business to support sustained long-term growth through four distinct pathways. Facility expansions are our first and most efficient growth pathway as we can expand services in established markets with our existing infrastructure and experienced staff. We added 132 beds to our existing facilities during the third quarter, bringing our total number of bed additions to 210 for the first nine months of the year. We are on track to meet our goal of adding approximately 300 beds in 2022.

"For our second growth pathway, we continue to develop wholly owned de novo facilities that meet the critical demand for behavioral healthcare services in underserved markets. There are significant opportunities across the country to address this unmet need at the local community level. We opened a 60-bed children's hospital in early July, as the first stage of our Montrose Behavioral Health Hospital operations in Chicago. In addition to the children's hospital, we expect to begin operations at our 101-bed adult hospital and the outpatient facility in 2023 following the renovations of these facilities.

"We continue to identify opportunities to expand our network of CTCs to address the critical need for addiction treatment, specifically for patients dealing with opioid use disorder. During the third quarter, we opened new CTCs in Indiana and Florida. This brings our total to four CTCs opened this year, supporting our objective to open at least six new CTCs in 2022. As the opioid crisis has continued to escalate across the country, our CTC facilities and programs are playing a vital role in addressing this national epidemic.

"A third important pathway for growth for Acadia is forming strategic partnerships with leading health systems across the country. We are proud to work with a growing number of premier health systems to expand behavioral healthcare treatment options in their respective communities. By working together, we can leverage our behavioral health expertise and implement best practices to deliver high quality care and positive clinical outcomes for more patients. During the third quarter, we opened a new facility with our joint venture partner, Covenant Health, in Knoxville, Tennessee. We also broke ground on a new state-of-the-art behavioral health treatment and teaching hospital with our joint venture partner, Henry Ford Health, in the Detroit, Michigan metropolitan area. We expect to commence operations at Maple Heights Behavioral Health, our joint venture with Lutheran Health Network of Indiana during the fourth quarter. An important aspect of many of our joint venture partnerships is the academic focus and training of future clinicians. During the quarter, our Belmont Behavioral Health Hospital in Philadelphia entered into a formal affiliation agreement with Thomas Jefferson University's Sidney Kimmel Medical College and Jefferson Health in Philadelphia, Pennsylvania, to further teaching and clinical care opportunities for students in behavioral healthcare.

"For our fourth pathway, we focus on identifying strategic acquisition opportunities that allow us to leverage our scale and expertise, make necessary investments for expansion and add service offerings to further enhance the continuum of care. We are fortunate to have a strong balance sheet that supports our ability to pursue acquisitions along with opportunities through our other important growth pathways," added Hunter.

Cash and Liquidity

Maintaining a strong financial position is a top priority for Acadia, providing the flexibility to pursue its growth initiatives and make strategic investments in its business. As of September 30, 2022, the Company had \$93.4 million in cash and cash equivalents. The Company had \$515 million available under its \$600 million revolving credit facility and its net leverage ratio was approximately 2.1x as of September 30, 2022.

During the third quarter, the Company substantially completed its repayment of amounts received pursuant to the Medicare Accelerated and Advanced Payment Program under the CARES Act. Of the \$45.2 million of advanced payments received in 2020, the Company repaid a total of \$25.1 million in 2021 and made additional payments of \$18.9 million through the first nine months of 2022. The Company will pay off the remaining balance of \$1.2 million in the fourth quarter of 2022. In the third quarter of 2022, the Company repaid the remaining half of the approximately \$39.3 million of 2020 payroll tax deferrals, which eliminated this liability.

2022 Guidance Range

Approximately \$60 million

Financial Guidance

Maintenance capital expenditures

Acadia today narrowed its previously announced financial guidance for 2022, as follows:

Revenue \$2.58 to \$2.60 billion Adjusted EBITDA, including income from the PRF \$611 to \$621 million Adjusted EBITDA, excluding income from the PRF \$595 to \$605 million Adjusted earnings per diluted share, including income from the PRF \$3.13 to \$3.23 Adjusted earnings per diluted share, excluding income from the PRF \$3.00 to \$3.10 Interest expense Approximately \$70 million Tax rate 25% to 26% Depreciation and amortization expense Approximately \$120 million Approximately \$30 million Stock compensation expense Operating cash flows \$360 to \$400 million Expansion capital expenditures \$210 to \$230 million

The Company's guidance does not include the impact of any future acquisitions, divestitures or transaction-related expenses.

Looking Ahead

Hunter added, "We look forward to hosting Acadia's first Investor Day on Wednesday, December 7, 2022, in New York City. Our management team will provide an in-depth look at our diverse service lines and our strategic initiatives to advance our leadership position in the behavioral healthcare industry.

"We are excited about the opportunities ahead for Acadia, as we remain focused on our primary objective to extend our market reach through our four defined growth pathways. Demand for our services continues to grow, and we believe we are well positioned to maintain our strong growth trajectory and meet our development targets for the year. Without question, the critical need for behavioral health treatment has become a primary focus for health officials, medical professionals, and lawmakers across the country, with depression and anxiety issues further amplified by the strains of the COVID-19 pandemic. Recent data from the Centers for Disease Control and Prevention showed the U.S. suicide rate rose four percent in 2021 after two consecutive years of declines, highlighting the critical need for early assessment and intervention. As a leading provider of behavioral healthcare services, we play a vital role in addressing this need, and we believe we have the right strategy in place to make a positive difference. We are proud of the important work we are doing as we continue to pursue a strategic direction that delivers greater value for our patients, the communities we serve, and our stockholders."

Conference Call

Acadia will hold a conference call to discuss its third quarter financial results at 9:00 a.m. Eastern Time on November 1, 2022. A live webcast of the conference call will be available at www.acadiahealthcare.com in the "Investors" section of the website. The webcast of the conference call will be available for 30 days.

About Acadia

Acadia is a leading provider of behavioral healthcare services across the United States. As of September 30, 2022, Acadia operated a network of 242 behavioral healthcare facilities with approximately 10,800 beds in 39 states and Puerto Rico. With more than 22,500 employees serving approximately 70,000 patients daily, Acadia is the largest stand-alone behavioral healthcare company in the U.S. Acadia provides behavioral healthcare services to its patients in a variety of settings, including inpatient psychiatric hospitals, specialty treatment facilities, residential treatment centers and outpatient clinics.

Forward-Looking Information

This press release contains forward-looking statements. Generally, words such as "may," "will," "should," "could," "anticipate," "expect," "intend," "estimate," "plan," "continue," and "believe" or the negative of or other variation on these and other similar expressions identify forward-looking statements. These forward-looking statements are made only as of the date of this press release. We do not undertake to update or revise the forwardlooking statements, whether as a result of new information, future events or otherwise. Forward-looking statements are based on current expectations and involve risks and uncertainties and our future results could differ significantly from those expressed or implied by our forward-looking statements. Factors that may cause actual results to differ materially include, without limitation, (i) the impact of the COVID-19 pandemic, including, without limitation, disruption to the U.S. economy and financial markets; reduced admissions and patient volumes; and increased costs relating to labor, supply chain and other expenditures; (ii) the impact of vaccine and other pandemic-related mandates imposed by local, state and federal authorities; (iii) potential difficulties in successfully integrating the operations of acquired facilities or realizing the expected benefits and synergies of our facility expansions, acquisitions, joint ventures and de novo transactions; (iv) Acadia's ability to add beds, expand services, enhance marketing programs and improve efficiencies at its facilities; (v) potential reductions in payments received by Acadia from government and third-party payors; (vi) the occurrence of patient incidents, governmental investigations, litigation and adverse regulatory actions, which could adversely affect the price of our common stock and result in substantial payments and incremental regulatory burdens; (vii) the risk that Acadia may not generate sufficient cash from operations to service its debt and meet its working capital and capital expenditure requirements; (viii) potential disruptions to our information technology systems or a cybersecurity incident; and (ix) potential operating difficulties, labor costs, client preferences, changes in competition and general economic or industry conditions that may prevent Acadia from realizing the expected benefits of its business strategies. These factors and others are more fully described in Acadia's periodic reports and other filings with the SEC.

Acadia Healthcare Company, Inc. Condensed Consolidated Statements of Operations (Unaudited)

	Three Months Ended September 30,			Nine	Nine Months Ended September 30,				
		2022		2021		2022		2021	
		(1	n thou	sands, excep	t per s	share amount	s)		
Revenue	\$	666,732	\$	587,559	\$	1,935,104	\$	1,720,914	
Salaries, wages and benefits (including equity-based compensation									
expense of \$7,240, \$8,923, \$21,745 and \$24,988, respectively)		352,582		309,118		1,027,732		922,684	
Professional fees		40,367		35,602		117,718		101,915	
Supplies		25,570		23,743		74,291		67,698	
Rents and leases		11,339		9,658		33,780		28,690	
Other operating expenses		88,993		76,502		255,355		222,263	
Income from provider relief fund		(7,656)		_		(16,206)		_	
Depreciation and amortization		29,573		27,805		87,627		78,349	
Interest expense, net		18,003		15,706		50,355		61,420	
Debt extinguishment costs		_		_		_		24,650	
Loss on impairment		_		1,079		_		24,293	
Transaction-related expenses		10,859	. <u></u>	3,035		18,381		9,320	
Total expenses		569,630	. <u> </u>	502,248		1,649,033		1,541,282	
Income from continuing operations before income taxes		97,102		85,311		286,071		179,632	
Provision for income taxes		24,056	. <u> </u>	17,411		69,183		42,948	
Income from continuing operations		73,046		67,900		216,888		136,684	
Loss from discontinued operations, net of taxes			<u></u>					(12,641)	
Net income		73,046		67,900		216,888		124,043	
Net income attributable to noncontrolling interests		(1,947)		(1,774)		(4,873)		(3,686)	
Net income attributable to Acadia Healthcare Company, Inc.	\$	71,099	\$	66,126	\$	212,015	\$	120,357	
Basic earnings per share attributable to Acadia Healthcare Company, Inc. stockholders:									
Income from continuing operations attributable to Acadia Healthcare									
Company, Inc.	\$	0.79	\$	0.74	\$	2.37	\$	1.50	
Loss from discontinued operations				_		_	\$	(0.14)	
Net income attributable to Acadia Healthcare Company, Inc.	\$	0.79	\$	0.74	\$	2.37	\$	1.36	
Diluted earnings per share attributable to Acadia Healthcare Company, Inc. stockholders:									
Income from continuing operations attributable to Acadia Healthcare									
Company, Inc.	\$	0.78	\$	0.73	\$	2.31	\$	1.47	
Loss from discontinued operations		_		_		_	\$	(0.14)	
Net income attributable to Acadia Healthcare Company, Inc.	\$	0.78	\$	0.73	\$	2.31	\$	1.33	
Weighted-average shares outstanding:									
Basic		89,833		88,962		89,607		88,684	
Diluted		91,723		90,889		91,668		90,604	

Acadia Healthcare Company, Inc. Condensed Consolidated Balance Sheets (Unaudited)

	September 30, 2022		December 31, 2021			
	(In t	(In thousands)				
ASSETS						
Current assets:						
Cash and cash equivalents	\$ 93,419	\$	133,813			
Accounts receivable, net	315,999)	281,332			
Other current assets	112,23	3	79,886			
Total current assets	521,650	5	495,031			
Property and equipment, net	1,908,993	3	1,771,159			
Goodwill	2,207,91	2	2,199,937			
Intangible assets, net	75,920)	70,145			
Deferred tax assets	2,983	3	3,080			
Operating lease right-of-use assets	135,62	7	133,761			
Other assets	90,01	1	94,965			
Total assets	\$ 4,943,10	\$	4,768,078			
LIABILITIES AND EQUITY						
Current liabilities:						
Current portion of long-term debt	\$ 21,250	\$	18,594			
Accounts payable	116,04	5	98,575			
Accrued salaries and benefits	109,654		137,845			
Current portion of operating lease liabilities	25,770		23,348			
Other accrued liabilities	128,29		126,499			
Total current liabilities	401,013	3	404,861			
Long-term debt	1,379,300	5	1,478,626			
Deferred tax liabilities	94,44	6	74,368			
Operating lease liabilities	117,47	3	116,841			
Other liabilities	118,92	3	110,505			
Total liabilities	2,111,16		2,185,201			
Redeemable noncontrolling interests	88,230	6	65,388			
Equity:						
Common stock	899)	890			
Additional paid-in capital	2,650,54	5	2,636,350			
Retained earnings (accumulated deficit)	92,26	1	(119,751)			
Total equity	2,743,70	3	2,517,489			
Total liabilities and equity	\$ 4,943,10	\$	4,768,078			

Acadia Healthcare Company, Inc. Condensed Consolidated Statements of Cash Flows (Unaudited)

	N	line Months End	ded Septe	September 30,		
		2022		2021		
		(In tho	usands)			
Operating activities:	•	•16.000	•	101010		
Net income	\$	216,888	\$	124,043		
Adjustments to reconcile net income to net cash provided by continuing operating activities:		07.607		5 0.040		
Depreciation and amortization		87,627		78,349		
Amortization of debt issuance costs		2,440		3,265		
Equity-based compensation expense		21,745		24,988		
Deferred income taxes		20,176		8,995		
Loss from discontinued operations, net of taxes				12,641		
Debt extinguishment costs		_		24,650		
Loss on impairment		_		24,293		
Other		2,422		881		
Change in operating assets and liabilities, net of effect of acquisitions:						
Accounts receivable, net		(35,538)		(8,610)		
Other current assets		(28,692)		(2,758)		
Other assets		3,373		(15,846)		
Accounts payable and other accrued liabilities		7,729		6,358		
Accrued salaries and benefits		(8,831)		18,820		
Other liabilities		10,303		(11,633)		
Government relief funds		(32,617)		(12,058)		
Net cash provided by continuing operating activities		267,025		276,378		
Net cash provided by discontinued operating activities		207,025		253		
Net cash provided by operating activities Net cash provided by operating activities		267,025	-	276,631		
Net eash provided by operating activities		207,023		270,031		
Investing activities:						
Cash paid for capital expenditures		(208,792)		(156,624)		
Proceeds from U.K. Sale				1,511,020		
Settlement of foreign currency derivatives		_		(84,795)		
Proceeds from sale of property and equipment		1,784		1,792		
Cash paid for purchase of finance lease		_		(31,401)		
Other		(6,802)		3,106		
Net cash (used in) provided by investing activities		(213,810)		1,243,098		
Financing activities:						
Borrowings on long-term debt		_		425,000		
Borrowings on revolving credit facility		_		430,000		
Principal payments on revolving credit facility		(85,000)		(330,000)		
Principal payments on long-term debt		(13,281)		(5,313)		
Repayment of long-term debt				(2,227,935)		
Payment of debt issuance costs		_		(7,964)		
Repurchase of shares for payroll tax withholding, net of proceeds from stock option exercises		(7,541)		16,072		
Contributions from noncontrolling partners in joint ventures		13,178		1,800		
Distributions to noncontrolling partners in joint ventures		(1,004)		(926)		
Other		39		(6,914)		
Net cash used in financing activities		(93,609)		(1,706,180)		
Effect of exchange rate changes on cash				4,067		
Effect of exchange rate changes on easi		_		7,007		
Net decrease in cash and cash equivalents		(40,394)		(182,384)		
Cash and cash equivalents at beginning of the period		133,813		378,697		
Cash and cash equivalents at end of the period	\$	93,419	\$	196,313		

Acadia Healthcare Company, Inc. Operating Statistics (Unaudited, Revenue in thousands)

	Three Months Ended September 30,				Nine Months Ended September 30,					
		2022		2021	% Change		2022		2021	% Change
U.S. Same Facility Results (1)										
Revenue	\$ 6	540,343	\$ 5	580,930	10.2%	\$1,8	359,200	\$1,7	703,906	9.1%
Patient Days	7	713,531	6	91,956	3.1%	2,1	110,129	2,0	068,842	2.0%
Admissions		45,445		45,192	0.6%	1	33,204	1	136,183	-2.2%
Average Length of Stay (2)		15.7		15.3	2.5%		15.8		15.2	4.3%
Revenue per Patient Day	\$	897	\$	840	6.9%	\$	881	\$	824	7.0%
Adjusted EBITDA margin (3)		30.5%		29.0%	150 bps		29.9%		28.0%	190 bps
Adjusted EBITDA margin excluding income from provider relief fund		29.3%		29.0%	30 bps		29.0%		28.0%	100 bps
U.S. Facility Results										
Revenue	\$ 6	666,732	\$ 5	87,559	13.5%	\$1,9	35,104	\$1,7	720,914	12.4%
Patient Days	7	738,702	7	701,352	5.3%	2,1	79,805	2,0	088,477	4.4%
Admissions		47,692		45,246	5.4%	1	39,930	1	136,384	2.6%
Average Length of Stay (2)		15.5		15.5	-0.1%		15.6		15.3	1.7%
Revenue per Patient Day	\$	903	\$	838	7.7%	\$	888	\$	824	7.7%
Adjusted EBITDA margin (3)		28.7%		28.3%	40 bps		28.3%		27.7%	60 bps
Adjusted EBITDA margin excluding income from provider relief fund		27.5%		28.3%	-80 bps		27.4%		27.7%	-30 bps

⁽¹⁾ Same facility results for the periods presented include facilities we have operated for more than one year and exclude certain closed services.

⁽²⁾ Average length of stay is defined as patient days divided by admissions.

⁽³⁾ For the three and nine months ended September 30, 2022, includes income from provider relief fund of \$7.7 million and \$16.2 million, respectively.

Acadia Healthcare Company, Inc. Reconciliation of Net Income Attributable to Acadia Healthcare Company, Inc. to Adjusted EBITDA (Unaudited)

	Three Months Ended September 30,			Nine Months Ended Sept			ptember 30,	
	2022		2021		2022			2021
				(in thou	sands	s)		
Net income attributable to Acadia Healthcare Company, Inc.	\$	71,099	\$	66,126	\$	212,015	\$	120,357
Net income attributable to noncontrolling interests		1,947		1,774		4,873		3,686
Loss from discontinued operations, net of taxes		_		_		_		12,641
Provision for income taxes		24,056		17,411		69,183		42,948
Interest expense, net		18,003		15,706		50,355		61,420
Depreciation and amortization		29,573		27,805		87,627		78,349
EBITDA		144,678		128,822		424,053		319,401
Adjustments:								
Equity-based compensation expense (a)		7,240		8,923		21,745		24,988
Transaction-related expenses (b)		10,859		3,035		18,381		9,320
Debt extinguishment costs (c)		_						24,650
Loss on impairment (d)		_		1,079				24,293
Adjusted EBITDA	\$	162,777	\$	141,859	\$	464,179	\$	402,652
Adjusted EBITDA margin		24.4%		24.1%		24.0%		23.4%
Adjusted EBITDA excluding income from provider relief fund	\$	155,121	\$	141,859	\$	447,973	\$	402,652
Adjusted EBITDA margin excluding income from provider relief fund		23.3%		24.1%		23.1%		23.4%
See footnotes on page 12.								

Acadia Healthcare Company, Inc. Reconciliation of Net Income Attributable to Acadia Healthcare Company, Inc. to Adjusted Income Attributable to Acadia Healthcare Company, Inc. (Unaudited)

	Three Months Ended September 30 Nine Months Ended September						
	2022	2021	2022	2021			
	(in the	per share amounts	s)				
Net income attributable to Acadia Healthcare Company, Inc.	\$ 71,099	\$ 66,126	\$ 212,015	\$ 120,357			
Loss from discontinued operations, net of taxes	_	_	_	12,641			
Adjustments to income:							
Transaction-related expenses (b)	10,859	3,035	18,381	9,320			
Debt extinguishment costs (c)	_	_	_	24,650			
Loss on impairment (d)	_	1,079	_	24,293			
Provision for income taxes	24,056	17,411	69,183	42,948			
Adjusted income from continuing operations before income taxes attributable to Acadia Healthcare Company, Inc.	106,014	87,651	299,579	234,209			
Income tax effect of adjustments to income (e)	27,148	22,508	76,662	62,709			
Adjusted income from continuing operations attributable to Acadia Healthcare Company, Inc.	78,866	65,143	222,917	171,500			
Income from provider relief fund, net of taxes	(5,579)	_	(11,809)	_			
Adjusted income from continuing operations attributable to Acadia Healthcare Company, Inc. excluding income from provider relief fund	\$ 73,287	\$ 65,143	\$ 211,108	\$ 171,500			
Weighted-average shares outstanding - diluted	91,723	90,889	91,668	90,604			
Adjusted income from continuing operations attributable to Acadia Healthcare Company, Inc. per diluted share Income from provider relief fund, net of taxes, per diluted share	\$ 0.86 (0.06)	\$ 0.72 —	\$ 2.43 (0.13)	\$ 1.89 			
Adjusted income from continuing operations attributable to Acadia Healthcare Company, Inc., excluding income from provider relief fund, per diluted share	\$ 0.80	\$ 0.72	\$ 2.30	\$ 1.89			

See footnotes on page 12.

Acadia Healthcare Company, Inc. Footnotes

We have included certain financial measures in this press release, including those listed below, which are "non-GAAP financial measures" as defined under the rules and regulations promulgated by the SEC. These non-GAAP financial measures include, and are defined, as follows:

- <u>EBITDA</u>: net income attributable to Acadia Healthcare Company, Inc. adjusted for net income attributable to noncontrolling interests, loss from discontinued operations, net of taxes, provision for income taxes, net interest expense and depreciation and amortization.
- <u>Adjusted EBITDA</u>: EBITDA adjusted for equity-based compensation expense, transaction-related expenses, debt extinguishment costs and loss on impairment.
- Adjusted EBITDA excluding income from provider relief fund: Adjusted EBITDA adjusted for income from provider relief fund.
- Adjusted EBITDA margin: Adjusted EBITDA divided by revenue.
- <u>Adjusted EBITDA margin excluding income from provider relief fund</u>: Adjusted EBITDA excluding income from provider relief fund divided by revenue.
- <u>Adjusted income from continuing operations before income taxes attributable to Acadia Healthcare Company, Inc.</u>: net income attributable to Acadia Healthcare Company, Inc. adjusted for loss from discontinued operations, net of taxes, transaction-related expenses, debt extinguishment costs, loss on impairment and provision for income taxes.
- <u>Adjusted income from continuing operations attributable to Acadia Healthcare Company, Inc.</u>: Adjusted income from continuing operations before income taxes attributable to Acadia Healthcare Company, Inc. adjusted for the income tax effect of adjustments to income.
- <u>Adjusted income from continuing operations attributable to Acadia Healthcare Company, Inc. excluding income from provider relief fund</u>: Adjusted income from continuing operations attributable to Acadia Healthcare Company, Inc. adjusted for income from provider relief fund.
- <u>Adjusted income attributable to Acadia Healthcare Company, Inc.</u>: the sum of Adjusted income from continuing operations before income taxes attributable to Acadia Healthcare Company, Inc. and income tax effect of adjustments to income.
- <u>Adjusted income attributable to Acadia Healthcare Company, Inc. excluding income from provider relief fund</u>: Adjusted income from continuing operations attributable to Acadia Healthcare Company, Inc. adjusted for income from provider relief fund.

The non-GAAP financial measures presented herein are supplemental measures of our performance and are not required by, or presented in accordance with, generally accepted accounting principles in the United States ("GAAP"). The non-GAAP financial measures presented herein are not measures of our financial performance under GAAP and should not be considered as alternatives to net income or any other performance measures derived in accordance with GAAP or as an alternative to cash flow from operating activities as measures of our liquidity. Our measurements of these non-GAAP financial measures may not be comparable to similarly titled measures of other companies. We have included information concerning the non-GAAP financial measures in this press release because we believe that such information is used by certain investors as measures of a company's historical performance. We believe these measures are frequently used by securities analysts, investors and other interested parties in the evaluation of issuers of equity securities, many of which present similar non-GAAP financial measures when reporting their results. Because the non-GAAP financial measures are not measurements determined in accordance with GAAP and are thus susceptible to varying calculations, the non-GAAP financial measures, as presented, may not be comparable to other similarly titled measures of other companies. Our presentation of these non-GAAP financial measures should not be construed as an inference that our future results will be unaffected by unusual or nonrecurring items.

The Company is not able to provide a reconciliation of projected Adjusted EBITDA and adjusted earnings per diluted share, where provided and whether including or excluding income from provider relief fund, to expected results due to the unknown effect, timing and potential significance of transaction-related expenses and the tax effect of such expenses.

- (a) Represents the equity-based compensation expense of Acadia.
- (b) Represents transaction-related expenses incurred by Acadia primarily related to termination, restructuring, management transition, acquisition and other similar costs.
- (c) Represents debt extinguishment costs recorded during the first quarter of 2021 in connection with the redemption of the 5.625% senior notes and 6.500% senior notes and the termination of the prior credit facility.
- (d) The Company opened a 260-bed replacement hospital in Pennsylvania and recorded a non-cash property impairment charge of \$23.2 million for the existing facility during the second quarter of 2021. Additionally, during the third quarter of 2021, the Company recorded a \$1.1 million non-cash property impairment charge for one facility in Louisiana resulting from hurricane damage.
- (e) Represents the income tax effect of adjustments to income based on tax rates of 25.6% and 25.7% for the three months ended September 30, 2022 and 2021, respectively, and 25.6% and 26.8% for the nine months ended September 30, 2022 and 2021, respectively.

Contacts

Gretchen Hommrich Vice President, Investor Relations (615) 861-6000